RGENCongressional Stock Trades
Repligen Corp
Biological Products, (No Diagnostic Substances)
Congressional stock trades in Repligen Corp (RGEN) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
7
Politicians Trading
2
Last Traded
Oct 31, 2025
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Lisa C. McClainR | Nov 21, 2025 | Oct 31, 2025 | Sell | $1,001 - $15,000 | +18.67% |
| Lisa C. McClainR | Nov 21, 2025 | Oct 30, 2025 | Sell | $1,001 - $15,000 | +22.36% |
| Lisa C. McClainR | Aug 13, 2025 | Jun 17, 2025 | Sell | $1,001 - $15,000 | +46.18% |
| Jefferson ShreveR | May 8, 2025 | Apr 7, 2025 | Sell | $15,001 - $50,000 | +52.35% |
Price History
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.